Overcoming the challenges within biopharmaceutical development; from bench to production
A Cross-Border event; access to cross-border expertise & infrastructure
Overcoming the challenges within biopharmaceutical development;
from bench to production
Achieving clinical grade products for clinical evaluation is a major challenge in the development of biopharmaceuticals. Under the framework of the Interreg project Skin-HUID, regional partners Basic Pharma and MosaMedix, together with the academic partners University of Maastricht, Antwerp and the Flemish Institute for Biotechnology (VIB) aim to bring a novel biopharmaceutical to the clinic and jointly overcome this hurdle.
The partners have joined forces to cover all phases in the development of biopharmaceuticals; discovery, proof of concept, validation and production.
The novel biopharmaceutical developed by the partners is based on a unique combination of a biological drug and electrical stimulation. The project focuses on the use of this combination in the extremely complicated treatment of melanoma, the most lethal form of skin cancer.
In 2019 this biopharmaceutical will be produced in the recently established GMP cleanroom facility, at Basic Pharma in Geleen. This facility enables the development of biopharmaceuticals from lab scale to the early clinical phases.
On May 16 we will introduce you to the challenges encountered within the drug development process of biopharmaceuticals and how the partners of the SkinHUID project bridged the gap between benchtop and production for the early clinical phases.
Topics covered during this symposium:
- Biopharmaceutical discovery
- Critical steps in the biopharmaceutical development from lab scale to GMP pilot scale
- Introduction to the recently established GMP cleanroom facility
- Spin-off companies pitching their businesses and challenges
Here we will keep you updated on the event. The program will be published in January 2019, registration will open in February 2019.